Liver fibrosis refers to a condition involving chronic damage to the liver which eventually creates a wound that never heals. This condition gradually replaces normal liver cells - which detoxify the food and liquid we consume - with more and more scar tissue until the organ no longer works. Scientists at the Salk Institute have identified a drug that halts this unchecked accumulation of scar tissue in the liver. The small molecule, called JQ1, prevented as well as reversed fibrosis in animals and could help the millions of people worldwide affected by liver fibrosis and cirrhosis, caused by alcoholism and diseases like hepatitis. These results were published in PNAS. Ronald Evans, professor and director of Salk's Gene Expression Laboratory and a Howard Hughes Medical Institute investigator, said, "After too much damage in the liver, the scar tissue itself causes more scar tissue. We can actually reverse liver fibrosis in animals and are now exploring potential therapeutic applications for humans." ‘Salk Institute researchers have identified a drug that halts the unchecked accumulation of scar tissue in the liver. This small molecule, called JQ1, prevented as well as reversed fibrosis in animals.’ When the liver is damaged, small collections of hepatic stellate cells that specialize in storing vitamin A are called upon to tend to the wound. These activated stellate cells shed their vitamin A, travel to the site of injury and create thick, fibrous scar tissue to wall off and repair the damage. However, with prolonged organ stress, healthy liver cells become replaced by scar tissue, eventually leading to organ failure. Michael Downes, a Salk senior scientist and author of the paper, said, "Traditional therapies targeting inflammation don't work because these cells have multiple ways to bypass the drug. In contrast, our strategy was to stop the fibrotic response at the genome level where these pathways converge." The search for the critical genome pathway struck gold, uncovering a regulatory protein, called BRD4, that is a master regulator of liver fibrosis. With this new knowledge in hand, the Salk team found JQ1 successfully inhibited BRD4 and halted the transformation of hepatic stellate cells into fiber-producing cells. This is good news, as JQ1 is a prototype of a new class of drugs currently being tested in human clinical trials for various cancers. Ruth Yu, a Salk staff researcher and one of the authors of the paper, said, "JQ1 doesn't just protect against the wound response, but also reverses the fibrotic response in mice." Evans, who also holds the March of Dimes Chair in Molecular and Developmental Biology, said, "Our results indicate that BRD4 is a driver of chronic fibrosis and a promising therapeutic target for treating liver disease. We think this discovery may also treat fibrosis in other organs, like the lung, pancreas and kidney." Source: Eurekalert << Telemedicine Effective, Patients & Providers Satisfied With... Top Travel Destinations in Asia Revealed >> Recommended Reading Vitamin D may Help Prevent Progress of Liver Fibrosis The findings of a recent animal study have revealed that synthetic vitamin D is effective in preventing the progress of liver fibrosis. READ MORE Immune Molecule That Plays Key Role in Liver Fibrosis can be Targeted by New Drugs Researchers have found that the immune molecule interleukin 33 (IL-33) plays a key role in the development of liver fibrosis. READ MORE New Therapy for Liver Fibrosis Discovered Calcipotriol - a synthetic form of vitamin D could be used as a potential new treatment for liver disease, say scientists. READ MORE Novel Drug Halts Liver Fibrosis NADPH oxidase (NOX) inhibitor therapy halts liver fibrosis in animal model of liver disease, say researchers. READ MORE Clinical Trials - Different Phases of the trial Clinical trials serve as a vital component for improving the treatment of medical conditions as they lead to higher standards of patient care. READ MORE Current Treatments for Liver Cancer Current Treatments for Liver Cancer (also known as hepatoma or hepatocellular carcinoma) can result in complete cure of the disease if it is detected early. READ MORE Drug Toxicity Drug toxicity is an adverse reaction of the body towards a drug that results as a side effect of a drug, reaction to a drug or drug abuse. READ MORE Fatty Liver Disease: A Growing Health Problem in India Non alcoholic fatty liver disease (NAFLD) is the leading cause of liver dysfunction worldwide and is a rapidly growing health problem in India. READ MORE Hepatitis A Hepatitis A is the most benign of the hepatitis viruses and usually has no long term side effects. Hepatitis A vaccine is available that is 95% effective in preventing the disease. READ MORE Living Donor Liver Transplant: What Are the Risks? The risk of dying as a result of a living donor liver segment removal is between 0.2-2.0%. The risk of morbidity is anywhere between 1.3% (in highly experienced centers) to 60%. READ MORE Milk Thistle Milk Thistle is a resourceful natural plant which has many medicinal benefits. In herbal medication milk thistle is used in cases of liver diseases. READ MORE Wilson's Disease This is a rare inherited systemic disorder of copper metabolism, affecting the liver mainly before other organs. READ MORE Most Popular on Medindia Color Blindness Calculator Blood Donation - Recipients Loram (2 mg) (Lorazepam) More News on: Drug ToxicityHepatitis AClinical Trials - Different Phases of the trialSignature Drug ToxicityLiverWilson's DiseaseMilk ThistleCurrent Treatments for Liver CancerFatty Liver Disease: A Growing Health Problem in IndiaLiving Donor Liver Transplant: What Are the Risks?